Literature DB >> 2044589

Disturbed myelination in patients with treated hyperphenylalaninaemia: evaluation with magnetic resonance imaging.

U Bick1, G Fahrendorf, A C Ludolph, P Vassallo, J Weglage, K Ullrich.   

Abstract

Cranial magnetic resonance imaging (MRI) was performed in nine treated adolescents with hyperphenylalaninaemia (HPA) in order to analyse possible changes in myelination. Three patients suffered from type I HPA, four from type II and two from type III (persistent HPA). Images were obtained with a 1.5 T unit using spin-echo-sequences. In all patients with type I or type II HPA, abnormal findings in the cerebral white matter were demonstrated including band-like and/or confluent patchy areas of high signal intensity predominantly in the peritrigonal region, with anterior and posterior periventricular extension and/or involvement of the subcortical white matter. The extent of MRI changes did not correlate with the initiation, duration or quality of dietary treatment. There was also no consistent relationship between electrophysiological changes and white matter abnormalities on MRI. Our findings suggest a disturbance of myelination in patients with treated HPA. These results correspond well with earlier neuropathological and biochemical studies in untreated patients.

Entities:  

Mesh:

Year:  1991        PMID: 2044589     DOI: 10.1007/bf01963563

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  26 in total

1.  Sequence of central nervous system myelination in human infancy. II. Patterns of myelination in autopsied infants.

Authors:  H C Kinney; B A Brody; A S Kloman; F H Gilles
Journal:  J Neuropathol Exp Neurol       Date:  1988-05       Impact factor: 3.685

2.  Focal signal-intensity variations in the posterior internal capsule: normal MR findings and distinction from pathologic findings.

Authors:  S Mirowitz; K Sartor; M Gado; R Torack
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

3.  The effects of diet discontinuation in children with phenylketonuria.

Authors:  R Koch; C G Azen; N Hurst; E G Friedman; K Fishler
Journal:  Eur J Pediatr       Date:  1987       Impact factor: 3.183

4.  Neuropathologic observations in phenylketonuria.

Authors:  L F Salguero; H H Itabashi; R J Allen
Journal:  Trans Am Neurol Assoc       Date:  1968

Review 5.  Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome.

Authors:  S E Waisbren; R R Schnell; H L Levy
Journal:  J Inherit Metab Dis       Date:  1980       Impact factor: 4.982

6.  Central nervous system lesions in disorders of amino-acid metabolism. A neuropathological study.

Authors:  J J Martin; W Schlote
Journal:  J Neurol Sci       Date:  1972       Impact factor: 3.181

7.  MR imaging of white matter disease in children.

Authors:  M A Nowell; R I Grossman; D B Hackney; R A Zimmerman; H I Goldberg; L T Bilaniuk
Journal:  AJR Am J Roentgenol       Date:  1988-08       Impact factor: 3.959

8.  Neurological deterioration in adult phenylketonuria.

Authors:  D Villasana; I J Butler; J C Williams; S M Roongta
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

9.  Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man.

Authors:  W Krause; M Halminski; L McDonald; P Dembure; R Salvo; D Freides; L Elsas
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

10.  Brain development in experimental hyperphenylalaninaemia: myelination.

Authors:  G Huether; R Kaus; V Neuhoff
Journal:  Neuropediatrics       Date:  1982-11       Impact factor: 1.947

View more
  24 in total

1.  Decreasing choline signal--a marker of phenylketonuria?

Authors:  M Dezortová; L Hejcmanová; M Hájek
Journal:  MAGMA       Date:  1996 Sep-Dec       Impact factor: 2.310

2.  Studies of multimodal evoked potentials in treated phenylketonuria: the pattern of vulnerability.

Authors:  A C Ludolph; U Vetter; K Ullrich
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

Review 3.  Late effects of phenylketonuria.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1995-12       Impact factor: 3.791

4.  Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations.

Authors:  V Leuzzi; S Rinalduzzi; F Chiarotti; P Garzia; G Trasimeni; N Accornero
Journal:  J Inherit Metab Dis       Date:  1998-06       Impact factor: 4.982

5.  Neurotransmitter positron emission tomographic-studies in adults with phenylketonuria, a pilot study.

Authors:  A M Paans; J Pruim; G P Smit; G Visser; A T Willemsen; K Ullrich
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

6.  Magnetic resonance imaging of the brain in adolescents with phenylketonuria and in one case of 6-pyruvoyl tetrahydropteridine synthase deficiency.

Authors:  J Pietz; U K Meyding-Lamadé; H Schmidt
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  Phenylketonuria: white-matter changes assessed by 3.0-T magnetic resonance (MR) imaging, MR spectroscopy and MR diffusion.

Authors:  T Scarabino; T Popolizio; M Tosetti; D Montanaro; G M Giannatempo; R Terlizzi; S Pollice; A Maiorana; N Maggialetti; A Carriero; V Leuzzi; U Salvolini
Journal:  Radiol Med       Date:  2009-03-10       Impact factor: 3.469

Review 8.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

9.  The effect of hyperphenylalaninaemia on the muscarinic acetylcholine receptor in the HPH-5 mouse brain.

Authors:  F A Hommes
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

10.  An occipito-temporal syndrome in adolescents with optimally controlled hyperphenylalaninaemia.

Authors:  H C Lou; P B Toft; J Andresen; I Mikkelsen; B Olsen; F Güttler; S Wieslander; O Henriksen
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.